Meloxicam for Patellar Tilt: Clinical Recommendation
Meloxicam is appropriate for short-term pain relief in patients with patellar tilt, as NSAIDs are effective for managing patellofemoral pain and have demonstrated safety and efficacy in knee conditions. 1
Evidence-Based Rationale
Primary Treatment Framework
The 2018 International Patellofemoral Research Retreat consensus strongly recommends exercise therapy as the cornerstone of patellofemoral pain management, specifically combining hip and knee exercises to reduce pain in the short, medium, and long term. 2 However, NSAIDs like meloxicam serve an important adjunctive role for symptomatic relief while patients engage in rehabilitation. 1
Role of Meloxicam in Patellar Conditions
Meloxicam provides effective short-term pain control for patellofemoral conditions through several mechanisms:
Rapid onset of action: Intramuscular meloxicam demonstrates faster pain relief than oral formulations in acute inflammatory conditions, though oral administration is appropriate for most cases. 3
Dosing considerations: Both 7.5 mg and 15 mg daily doses show comparable efficacy, with 15 mg providing more robust analgesia without significantly increased adverse effects. 4, 5
Safety profile: Meloxicam at 15 mg daily does not markedly increase gastrointestinal bleeding or wound complications compared to more selective COX-2 inhibitors like celecoxib, while offering substantial cost savings ($183 per prescription). 5
Clinical Application Algorithm
For acute patellar tilt with pain:
Initiate meloxicam 15 mg once daily for short-term symptom control (typically 7-14 days). 1, 6
Simultaneously begin exercise therapy focusing on hip and knee strengthening, as this addresses the underlying biomechanical dysfunction causing patellar maltracking. 2
Consider prefabricated foot orthoses if the patient demonstrates favorable response to treatment direction tests (e.g., improved squat mechanics with orthoses in place). 2
Add patellar taping if symptoms are severe enough to hinder rehabilitation participation, as this provides passive correction of patellar maltracking. 2, 1
Important Caveats
Duration limitations: NSAIDs should be used for short-term relief only, not as long-term monotherapy. 1 The evidence supports their use primarily in the initial phase while establishing an exercise program. 2
Contraindications to monitor: Exercise caution in patients with renal impairment, gastrointestinal disease history, or cardiovascular risk factors, though meloxicam's COX-2 selectivity provides relative safety advantages. 7, 5
Avoid passive-only approaches: Patellofemoral mobilizations in isolation and electrophysical agents are not recommended, as they lack efficacy for patellofemoral pain. 2
Post-Surgical Context
If patellar tilt occurs after total knee arthroplasty, meloxicam remains safe and effective:
No increased bleeding risk: Meloxicam does not increase transfusion or readmission rates even in chronically anticoagulated patients post-TKA. 8
Improved outcomes: Patients receiving meloxicam after TKA demonstrate reduced manipulation rates and decreased opioid consumption at 90 days. 8
Imaging assessment: Axial radiographs adequately demonstrate patellar tilt severity and guide treatment decisions. 9, 10, 9
Optimal Management Strategy
The most effective approach combines meloxicam for immediate pain control with exercise therapy targeting hip abductors, hip external rotators, and quadriceps to address the dynamic valgus and patellar maltracking underlying the condition. 2, 1 This combined intervention approach is superior to either modality alone and should be implemented from the outset. 2
Education must accompany all interventions, emphasizing that pain does not equal damage and that progressive loading through exercise is essential for long-term resolution. 2, 11